Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
暂无分享,去创建一个
G. Mills | Z. Ju | M. Birrer | P. Fracasso | S. Waggoner | R. Coleman | C. Aghajanian | S. Westin | S. Modesitt | R. Schilder | C. Mathews | M. Sill | Sanghoon Lee | K. Moore | Lainie P Martin
[1] Amy M. Sitapati,et al. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] G. Mills,et al. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response , 2017, Nature Communications.
[3] G. Mills,et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers , 2017, Science Translational Medicine.
[4] G. Mills,et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[6] P. Thaker,et al. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. , 2015, Gynecologic oncology.
[7] A. Oza,et al. Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. , 2015, Journal of Clinical Oncology.
[8] E. Van Cutsem,et al. A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors , 2014, Clinical Cancer Research.
[9] H. Mackay,et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. , 2014, Gynecologic oncology.
[10] T. Herzog,et al. Endometrial cancer: a review and current management strategies: part II. , 2014, Gynecologic oncology.
[11] J. Desai,et al. A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors. , 2014 .
[12] R. Broaddus,et al. The Search Continues: Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer , 2014, International Journal of Gynecologic Cancer.
[13] K. Leslie,et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. , 2014, Gynecologic oncology.
[14] H. Mackay,et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer , 2014, Cancer.
[15] A. Tolcher,et al. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma , 2014, Cancer Chemotherapy and Pharmacology.
[16] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[17] B. Weber,et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO , 2013, British Journal of Cancer.
[18] D. Matei,et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial , 2013, British Journal of Cancer.
[19] T. Petit,et al. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study , 2013, Targeted Oncology.
[20] G. Mills,et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer , 2012, Genome research.
[21] Gordon B Mills,et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. , 2012, Cancer cell.
[22] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[23] H. Mackay,et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Mills,et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. , 2011, Cancer discovery.
[25] J. Blenis,et al. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.
[26] A. Tolcher,et al. Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. Broaddus,et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma , 2010, Cancer.
[28] Francesca Molinari,et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. , 2010, The Journal of clinical investigation.
[29] H. Aburatani,et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas , 2009, British Journal of Cancer.
[30] A. Jimeno,et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[32] Ralph Weissleder,et al. Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.
[33] Pier Paolo Pandolfi,et al. The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.
[34] Roy S Herbst,et al. KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.
[35] Hong Wang,et al. PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia , 2006, Clinical Cancer Research.
[36] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[37] Yiling Lu,et al. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.
[38] Frank McCormick,et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. , 2005, Cancer research.
[39] P. Dennis,et al. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[40] Mef Nilbert,et al. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis , 2002, Cancer.
[41] Takashi Tsuruo,et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.